← Eichor
Condition: Diffuse Cutaneous Systemic Sclerosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Diffuse Cutaneous Systemic Sclerosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 92 location(s) · Novartis Pharmaceuticals · NCT06655896Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07000916Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Phase 2 · 9 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06375005Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Phase N/A · 1 location(s) · Duke University · NCT03276923Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 1 location(s) · Hospital for Special Surgery, New York · NCT03844061A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Ass
Phase 3 · 10 location(s) · GlaxoSmithKline · NCT06716606Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With
Phase 3 · 1 location(s) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Banglade · NCT06936215Controlling Hyperactive Immunity With Long-lived Lymphocytes
Phase 1/Phase 2 · 6 location(s) · Quell Therapeutics Limited · NCT07473154The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
Phase 4 · 1 location(s) · Peking University Third Hospital · NCT06546540Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT07256418Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NA · 1 location(s) · Boston University · NCT07090226EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Phase 2 · 6 location(s) · Mediar Therapeutics · NCT07287670A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Phase 2 · 3 location(s) · Galderma R&D · NCT07047690Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT06387654A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 128 location(s) · Novartis Pharmaceuticals · NCT06470048Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Phase 2 · 3 location(s) · Paul Szabolcs · NCT03630211Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Phase 2 · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT05149768
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.